Fig. 3: In vivo antiviral activity of JNJ-9676 against SARS-CoV-2.
From: A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
a, Schematic of a pre-exposure Syrian golden hamster experiment (data are shown in b–e). b,c, Individual datapoints per treatment group. n = 5 animals per group. Data are mean ± s.d. The mean differences between groups are calculated using one-way analysis of variance with Šídák’s multiple-comparison correction. b, The viral load in the indicated lung. The dotted line represents the lower limit of detection (LOD). c, Infectious virus in the lung. The dotted line represents the lower limit of quantification (LLoQ). d, The cumulative histopathology score. n = 5 animals per group. Individual datapoints per treatment group represent the median with the 95% confidence intervals. The dotted line represents a median lung score of 1.25 in healthy, untreated, non-infected animals. The differences between groups were calculated using the nonparametric Kruskal–Wallis tests with Benjamini–Hochberg false-discovery-rate multiple-comparison correction. e, Haematoxylin and eosin (H&E) staining of left lung lobe. Top left, the focal area of bronchopneumonia (green arrows), perivascular (red arrows) and peribronchial inflammation (blue arrows). Bottom left, no bronchopneumonia. Limited perivascular (red arrows) inflammation is indicated. Top right, no bronchopneumonia. Limited but significant perivascular (red arrows) inflammation and normal bronchi (blue arrows) are indicated. Bottom right, no bronchopneumonia. Normal bronchial (blue arrows) and vascular (red arrows) structures are indicated. f, Schematic of a therapeutic Syrian golden hamster experiment. g,h, Individual data points per treatment group. n = 5 per group. Data are mean ± s.d. The mean differences between groups were calculated as in b and c. The viral load (g) and infectious virus (h) in the lung is shown. IHC, immunohistochemistry. The doses reflect the amount of compound given for each administration.
